MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress) - Archive ouverte HAL
Article Dans Une Revue Clinical Lymphoma, Myeloma & Leukemia Année : 2022

MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)

Fichier non déposé

Dates et versions

hal-04744738 , version 1 (19-10-2024)

Identifiants

Citer

Rodrigo Ito, Toby Eyre, Nirav Shah, Steven Le Gouill, Martin Dreyling, et al.. MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress). Clinical Lymphoma, Myeloma & Leukemia, 2022, 22, pp.S395-S396. ⟨10.1016/s2152-2650(22)01570-1⟩. ⟨hal-04744738⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

More